董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rolland Carlson | 男 | Chief Executive Officer, President and Director | 61 | 90.04万美元 | 未持股 | 2016-04-12 |
| R. Dean Hautamaki | 男 | Director | 53 | 2.50万美元 | 未持股 | 2016-04-12 |
| Makoto Kaneshiro | 男 | Director | 57 | 2.50万美元 | 未持股 | 2016-04-12 |
| Joel Kanter | 男 | Director | 59 | 3.00万美元 | 未持股 | 2016-04-12 |
| William McKenzie | 男 | Director | 64 | 2.50万美元 | 未持股 | 2016-04-12 |
| Robert Schueren | 男 | Director | 54 | 5.50万美元 | 未持股 | 2016-04-12 |
| Ivan Trifunovich | 男 | Executive Chairman of the Board | 53 | 81.42万美元 | 未持股 | 2016-04-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael P. Henighan | 男 | Chief Financial Officer, Treasurer and Secretary | 63 | 33.93万美元 | 未持股 | 2016-04-12 |
| Rolland Carlson | 男 | Chief Executive Officer, President and Director | 61 | 90.04万美元 | 未持股 | 2016-04-12 |
董事简历
中英对照 | 中文 | 英文- Rolland Carlson
-
Rolland Carlson，自2015年5月起担任首席执行官、总裁兼董事。他于2006年4月至2014年5月间担任Asuragen, Inc.（分子诊断公司，专注于个性化诊断）的总裁兼董事；2013年1月至2014年5月间担任Asuragen, Inc.的首席执行官，2012年1月至12月间担任首席运营官。在Asuragen, Inc.时，他成立了Mirna Therapeutics（Asuragen的资产剥离公司，开发新型微小核糖核苷酸基础疗法，目前正在进行I期临床试验，用于肝癌和其他癌症）。在加入Asuragen之前， 他在Abbott Laboratories担任了业务开发及许可、全球医疗产品副总裁、the Vysis, Inc.（Abbott的全资子公司）的副总裁和全球总经理等多个高级职位。在他事业早期，他负责业务开发、许可和战略规划，以建立新的制药和诊断平台，用于Abbott的the Ross Division的儿科和女性医疗保健渠道，并且经营着Abbott的全球定制生物制药和特殊仿制药业务。他自2015年4月起担任Pristine, Inc.的董事。他获得了Southern Illinois University - Carbondale的生物学学士学位、运动生理学硕士学位和植物学博士学位。
Rolland Carlson has served as our Chief Executive Officer, President and director since May 2015. Dr. Carlson served as President and Director of Asuragen, Inc., a molecular diagnostic company specializing in personalized diagnostics, from April 2006 to May 2014. Dr. Carlson also served as Chief Executive Officer of Asuragen, Inc. from January 2013 to May 2014 and Chief Operating Officer of Asuragen, Inc. from January 2012 to December 2012. While at Asuragen, Inc., Dr. Carlson founded Mirna Therapeutics, a spin-out of Asuragen, which has developed novel miRNA-based therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to joining Asuragen, Dr. Carlson held several senior positions at Abbott Laboratories, including Vice President, Business Development & Licensing, Global Medical Products and Vice President and Global General Manager of the Vysis, Inc., a wholly-owned subsidiary of Abbott. Earlier in his career, Dr. Carlson was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and women’s health channels of the Ross Division of Abbott, and ran Abbott’s global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson has served on the board of directors of Pristine, Inc. since April 2015. Dr. Carlson received a B.A. in biological sciences, an M.A. in Exercise Physiology and a Ph.D. in Botany from Southern Illinois University - Carbondale. - Rolland Carlson，自2015年5月起担任首席执行官、总裁兼董事。他于2006年4月至2014年5月间担任Asuragen, Inc.（分子诊断公司，专注于个性化诊断）的总裁兼董事；2013年1月至2014年5月间担任Asuragen, Inc.的首席执行官，2012年1月至12月间担任首席运营官。在Asuragen, Inc.时，他成立了Mirna Therapeutics（Asuragen的资产剥离公司，开发新型微小核糖核苷酸基础疗法，目前正在进行I期临床试验，用于肝癌和其他癌症）。在加入Asuragen之前， 他在Abbott Laboratories担任了业务开发及许可、全球医疗产品副总裁、the Vysis, Inc.（Abbott的全资子公司）的副总裁和全球总经理等多个高级职位。在他事业早期，他负责业务开发、许可和战略规划，以建立新的制药和诊断平台，用于Abbott的the Ross Division的儿科和女性医疗保健渠道，并且经营着Abbott的全球定制生物制药和特殊仿制药业务。他自2015年4月起担任Pristine, Inc.的董事。他获得了Southern Illinois University - Carbondale的生物学学士学位、运动生理学硕士学位和植物学博士学位。
- Rolland Carlson has served as our Chief Executive Officer, President and director since May 2015. Dr. Carlson served as President and Director of Asuragen, Inc., a molecular diagnostic company specializing in personalized diagnostics, from April 2006 to May 2014. Dr. Carlson also served as Chief Executive Officer of Asuragen, Inc. from January 2013 to May 2014 and Chief Operating Officer of Asuragen, Inc. from January 2012 to December 2012. While at Asuragen, Inc., Dr. Carlson founded Mirna Therapeutics, a spin-out of Asuragen, which has developed novel miRNA-based therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to joining Asuragen, Dr. Carlson held several senior positions at Abbott Laboratories, including Vice President, Business Development & Licensing, Global Medical Products and Vice President and Global General Manager of the Vysis, Inc., a wholly-owned subsidiary of Abbott. Earlier in his career, Dr. Carlson was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and women’s health channels of the Ross Division of Abbott, and ran Abbott’s global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson has served on the board of directors of Pristine, Inc. since April 2015. Dr. Carlson received a B.A. in biological sciences, an M.A. in Exercise Physiology and a Ph.D. in Botany from Southern Illinois University - Carbondale.
- R. Dean Hautamaki
-
R. Dean Hautamaki是董事。他自2007年5月以来担任我们的董事。他是实习医师，自2005年1月以来是位于佛罗里达，塔拉哈西的佛罗里达州立大学医学院（Florida State University College of Medicine）的临床医学教授助理。从2003年9月到2005年12月他是位于佛罗里达州，萨拉索塔的Sarasota Memorial Hospital医学部的主席。从1997年9月到2005年12月他是位于佛罗里达州，萨拉索塔的Lung Associates of Sarasota的合伙人。他撰写了12多篇论文并出席数个会议。
R. Dean Hautamaki has served as our director since May 2007. Since September 2008 he has been a practicing physician with Hautamaki & Horiuchi Personal Physicians of Sarasota, and he has been the Assistant Clinical Professor of Medicine at the Florida State University College of Medicine in Tallahassee, Florida since January 2005. Dr. Hautamaki is Chairman of the Department of Medicine at Sarasota Memorial Hospital in Sarasota, Florida. From September 1997 through December 2005 he was a partner at Lung Associates of Sarasota in Sarasota, Florida. Dr. Hautamaki has authored over 12 papers and presented in several conferences. He also serves on the board of directors of two private biotechnology start-up companies, Fibralign Corporation and First Wave Technologies, Inc. - R. Dean Hautamaki是董事。他自2007年5月以来担任我们的董事。他是实习医师，自2005年1月以来是位于佛罗里达，塔拉哈西的佛罗里达州立大学医学院（Florida State University College of Medicine）的临床医学教授助理。从2003年9月到2005年12月他是位于佛罗里达州，萨拉索塔的Sarasota Memorial Hospital医学部的主席。从1997年9月到2005年12月他是位于佛罗里达州，萨拉索塔的Lung Associates of Sarasota的合伙人。他撰写了12多篇论文并出席数个会议。
- R. Dean Hautamaki has served as our director since May 2007. Since September 2008 he has been a practicing physician with Hautamaki & Horiuchi Personal Physicians of Sarasota, and he has been the Assistant Clinical Professor of Medicine at the Florida State University College of Medicine in Tallahassee, Florida since January 2005. Dr. Hautamaki is Chairman of the Department of Medicine at Sarasota Memorial Hospital in Sarasota, Florida. From September 1997 through December 2005 he was a partner at Lung Associates of Sarasota in Sarasota, Florida. Dr. Hautamaki has authored over 12 papers and presented in several conferences. He also serves on the board of directors of two private biotechnology start-up companies, Fibralign Corporation and First Wave Technologies, Inc.
- Makoto Kaneshiro
-
Makoto Kaneshiro是董事。他自2005年3月以来担任我们的董事。他是日本Genetic Devices, Co., Ltd.的创始成员，在那里他自2008年10月以来担任执行副总裁和董事会成员。从2003年到2004年他是日本公开上市贸易公司Sega Corporation董事会成员。他从耶鲁大学（Yale University ）获得工商管理硕士学位。
Makoto Kaneshiro has served as our director since March 2005. Mr. Kaneshiro is a founding member of Genetic Devices, Co., Ltd. in Japan, where he has been an executive vice president and member of the Board since October 2008. From 2003 to 2004 Mr. Kaneshiro was a member of the board of directors of Sega Corporation which was a publicly traded company in Japan. He holds an MBA from Yale University. - Makoto Kaneshiro是董事。他自2005年3月以来担任我们的董事。他是日本Genetic Devices, Co., Ltd.的创始成员，在那里他自2008年10月以来担任执行副总裁和董事会成员。从2003年到2004年他是日本公开上市贸易公司Sega Corporation董事会成员。他从耶鲁大学（Yale University ）获得工商管理硕士学位。
- Makoto Kaneshiro has served as our director since March 2005. Mr. Kaneshiro is a founding member of Genetic Devices, Co., Ltd. in Japan, where he has been an executive vice president and member of the Board since October 2008. From 2003 to 2004 Mr. Kaneshiro was a member of the board of directors of Sega Corporation which was a publicly traded company in Japan. He holds an MBA from Yale University.
- Joel Kanter
-
Joel Kanter是董事。他自2007年6月以来担任董事。他在金融服务行业工作超过30年，一直专注于为小型和中型公司提供股权和过桥融资。他担任私人投资公司Windy City, Inc.的总裁，是公开上市贸易公司Walnut Financial Services, Inc.的首席执行官和总裁。他目前在Dr. Tattoff, Inc., Magna-Lab, Inc.和Medgenics, Inc.董事会工作，以及负责一些私人问题，过去的五年里他在I-Flow Corporation, Pet DRx Corporation和Vyteris, Inc.董事会工作。他从Tulane University获得政治科学和心理学学士学位。
Joel Kanter is the Chairman of the Board of the Company. Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999 Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company Nasdaq: WNUT. Walnut Financial's primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million. From 1978 - 1980 Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton. From 1980 - 1983 Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas. Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies. Mr. Kanter is a National Association of Corporate Directors "Governance Fellow." Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country's first Online University. - Joel Kanter是董事。他自2007年6月以来担任董事。他在金融服务行业工作超过30年，一直专注于为小型和中型公司提供股权和过桥融资。他担任私人投资公司Windy City, Inc.的总裁，是公开上市贸易公司Walnut Financial Services, Inc.的首席执行官和总裁。他目前在Dr. Tattoff, Inc., Magna-Lab, Inc.和Medgenics, Inc.董事会工作，以及负责一些私人问题，过去的五年里他在I-Flow Corporation, Pet DRx Corporation和Vyteris, Inc.董事会工作。他从Tulane University获得政治科学和心理学学士学位。
- Joel Kanter is the Chairman of the Board of the Company. Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999 Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company Nasdaq: WNUT. Walnut Financial's primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million. From 1978 - 1980 Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton. From 1980 - 1983 Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas. Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies. Mr. Kanter is a National Association of Corporate Directors "Governance Fellow." Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country's first Online University.
- William McKenzie
-
William McKenzie是董事。他自2013年12月加入我们董事会。他在全球生命科学和诊断领域建立新业务上拥有超过25年的经验。自2010年以来他担任PerkinElmer分子诊断部的副总裁和总经理。加入PerkinElmer后，他自2005年以来担任各种职位，最初担任业务发展总监，然后是分子医学的战略营销总监，之后是遗传筛查的全球业务总监。在此之前，他在Millipore工作超过12年，职位的责任也越来越大。他从马萨诸塞大学（University of Massachusetts）获得生物学学士学位和硕士学位，在凯洛格管理学院（Kellogg School of Management）负责企业对企业的营销项目。
William McKenzie joined our Board in December 2013. Mr. McKenzie is a business leader with a strong technical background in nucleic acid purification, immunoassay, genetics and clinical lab medicine with over 25 years of experience building new businesses in the global life sciences and diagnostics sectors. He has served as a senior partner at Upstart Life Science, a management consultancy company, since 2012 and as Vice President and General Manager at Seracare during 2014. Mr. McKenzie held various positions at PerkinElmer from 2005 until 2012 including Business Development Director and Strategic Marketing Director of Molecular Medicine, Global Business Strategist of Genetic Screening, and Vice President and General Manager of Molecular Diagnostics. Prior to that, Mr. McKenzie worked for Millipore in positions of increasing responsibility, most notably as Strategic Marketing Director of Bioscience and General Manager of OEM Healthcare. Mr. McKenzie holds BS and MS degrees in Biology from the University of Massachusetts, is a member of the American Society for Clinical Pathology and is a registered clinical chemist. - William McKenzie是董事。他自2013年12月加入我们董事会。他在全球生命科学和诊断领域建立新业务上拥有超过25年的经验。自2010年以来他担任PerkinElmer分子诊断部的副总裁和总经理。加入PerkinElmer后，他自2005年以来担任各种职位，最初担任业务发展总监，然后是分子医学的战略营销总监，之后是遗传筛查的全球业务总监。在此之前，他在Millipore工作超过12年，职位的责任也越来越大。他从马萨诸塞大学（University of Massachusetts）获得生物学学士学位和硕士学位，在凯洛格管理学院（Kellogg School of Management）负责企业对企业的营销项目。
- William McKenzie joined our Board in December 2013. Mr. McKenzie is a business leader with a strong technical background in nucleic acid purification, immunoassay, genetics and clinical lab medicine with over 25 years of experience building new businesses in the global life sciences and diagnostics sectors. He has served as a senior partner at Upstart Life Science, a management consultancy company, since 2012 and as Vice President and General Manager at Seracare during 2014. Mr. McKenzie held various positions at PerkinElmer from 2005 until 2012 including Business Development Director and Strategic Marketing Director of Molecular Medicine, Global Business Strategist of Genetic Screening, and Vice President and General Manager of Molecular Diagnostics. Prior to that, Mr. McKenzie worked for Millipore in positions of increasing responsibility, most notably as Strategic Marketing Director of Bioscience and General Manager of OEM Healthcare. Mr. McKenzie holds BS and MS degrees in Biology from the University of Massachusetts, is a member of the American Society for Clinical Pathology and is a registered clinical chemist.
- Robert Schueren
-
Robert Schueren是董事。他自2014年1月加入我们董事会。他在生命科学和诊断公司担任领导职位20多年。他自2013年4月以来担任IntegenX Inc.的首席执行官和董事会成员。之前他是Genomics for Agilent Technologies的副总裁和总经理。2010年加入Agilent之前，他于2006年加入Genentech, Inc.，担任临床生物标志和业务（Clinical Biomarkers and Operations）的全球主管，分子医学实验室（Molecular Medicine Labs）的全球副主管。他获得天普大学（Temple University）药学学士学位。
Robert Schueren has served as our Chief Operating Officer since January 2019. Prior to joining Natera, Mr. Schueren served as chief executive officer and president of IntegenX Inc., a biotechnology company, from March 2013 to January 2019. Mr. Schueren served as vice president and general manager of the Genomics Solutions division at Agilent Technologies Inc. from January 2010 to January 2013; and prior to that, Mr. Schueren served at various companies including Genentech, Inc. and Arcturus Bioscience. Mr. Schueren holds a Bachelor of Science in Pharmacy from Temple University. - Robert Schueren是董事。他自2014年1月加入我们董事会。他在生命科学和诊断公司担任领导职位20多年。他自2013年4月以来担任IntegenX Inc.的首席执行官和董事会成员。之前他是Genomics for Agilent Technologies的副总裁和总经理。2010年加入Agilent之前，他于2006年加入Genentech, Inc.，担任临床生物标志和业务（Clinical Biomarkers and Operations）的全球主管，分子医学实验室（Molecular Medicine Labs）的全球副主管。他获得天普大学（Temple University）药学学士学位。
- Robert Schueren has served as our Chief Operating Officer since January 2019. Prior to joining Natera, Mr. Schueren served as chief executive officer and president of IntegenX Inc., a biotechnology company, from March 2013 to January 2019. Mr. Schueren served as vice president and general manager of the Genomics Solutions division at Agilent Technologies Inc. from January 2010 to January 2013; and prior to that, Mr. Schueren served at various companies including Genentech, Inc. and Arcturus Bioscience. Mr. Schueren holds a Bachelor of Science in Pharmacy from Temple University.
- Ivan Trifunovich
-
Ivan Trifunovich是首席执行官，总裁和董事。自2012年3月以来他担任我们的首席执行官，总裁和董事。他从2010年10月到2012年9月担任Helicos BioSciences Corporation8的总裁，首席执行官和董事长。他自2008年8月以来是生命科学行业全球公司的战略顾问。之前，他从2001年12月到2008年8月担任分子诊断公司Third Wave Technologies, Inc.的高级副总裁。加入Third Wave Technologies, Inc.之前，他连续担任Pharmacia Corp.电子商务的副总裁，研究战略和运营的副总裁。加入Pharmacia之前，他是Johnson & Johnson, Inc.新产品营销的总监。他在Bristol-Myers Squibb, Inc.开始职业生涯，担任实验科学家，并在那里担任数个职位，责任不断增加。他从UCLA（加州大学洛杉矶分校）获得有机化学博士学位，从宾夕法尼亚大学沃顿商学院（University of Pennsylvania's Wharton School of Business）获得工商管理硕士学位。
Ivan Trifunovich has served as our Executive Chairman of the Board of Directors since May 2015 and served as our Chief Executive Officer and President from March 2012 until May 2015. Dr. Trifunovich has served as a director since March 2012. Dr. Trifunovich has served as Vice President, Head of Asia Pacific for Exact Sciences Corporation since July 2015. Dr. Trifunovich served as President, Chief Executive Officer and Chairman of the Board of Helicos BioSciences Corporation1 from October 2010 to September 2012. Since August 2008 Dr. Trifunovich has served as a strategic consultant to global companies in the life sciences industry. Previously, Dr. Trifunovich served as the Senior Vice President of Third Wave Technologies, Inc., a molecular diagnostics company, from December 2001 through August 2008. Prior to joining Third Wave Technologies, Inc., Dr. Trifunovich held successive positions as Vice President of e-Business and Vice President of Research Strategy and Operations at Pharmacia Corp. Prior to joining Pharmacia, Dr. Trifunovich was a Director of New Product Marketing at Johnson & Johnson, Inc. He began his career at Bristol-Myers Squibb, Inc. as a bench scientist, where he held several positions of increasing responsibility. Dr. Trifunovich received his Ph.D. in organic chemistry at UCLA and an MBA at the University of Pennsylvania’s Wharton School of Business. - Ivan Trifunovich是首席执行官，总裁和董事。自2012年3月以来他担任我们的首席执行官，总裁和董事。他从2010年10月到2012年9月担任Helicos BioSciences Corporation8的总裁，首席执行官和董事长。他自2008年8月以来是生命科学行业全球公司的战略顾问。之前，他从2001年12月到2008年8月担任分子诊断公司Third Wave Technologies, Inc.的高级副总裁。加入Third Wave Technologies, Inc.之前，他连续担任Pharmacia Corp.电子商务的副总裁，研究战略和运营的副总裁。加入Pharmacia之前，他是Johnson & Johnson, Inc.新产品营销的总监。他在Bristol-Myers Squibb, Inc.开始职业生涯，担任实验科学家，并在那里担任数个职位，责任不断增加。他从UCLA（加州大学洛杉矶分校）获得有机化学博士学位，从宾夕法尼亚大学沃顿商学院（University of Pennsylvania's Wharton School of Business）获得工商管理硕士学位。
- Ivan Trifunovich has served as our Executive Chairman of the Board of Directors since May 2015 and served as our Chief Executive Officer and President from March 2012 until May 2015. Dr. Trifunovich has served as a director since March 2012. Dr. Trifunovich has served as Vice President, Head of Asia Pacific for Exact Sciences Corporation since July 2015. Dr. Trifunovich served as President, Chief Executive Officer and Chairman of the Board of Helicos BioSciences Corporation1 from October 2010 to September 2012. Since August 2008 Dr. Trifunovich has served as a strategic consultant to global companies in the life sciences industry. Previously, Dr. Trifunovich served as the Senior Vice President of Third Wave Technologies, Inc., a molecular diagnostics company, from December 2001 through August 2008. Prior to joining Third Wave Technologies, Inc., Dr. Trifunovich held successive positions as Vice President of e-Business and Vice President of Research Strategy and Operations at Pharmacia Corp. Prior to joining Pharmacia, Dr. Trifunovich was a Director of New Product Marketing at Johnson & Johnson, Inc. He began his career at Bristol-Myers Squibb, Inc. as a bench scientist, where he held several positions of increasing responsibility. Dr. Trifunovich received his Ph.D. in organic chemistry at UCLA and an MBA at the University of Pennsylvania’s Wharton School of Business.
高管简历
中英对照 | 中文 | 英文- Michael P. Henighan
Michael P. Henighan自2014年8月起担任公司首席财务官。除了 Henighan的此项任命之外，我们还与 Henighan签订了高管就业协议，2014年8月25日正式生效。根据就业协议， Henighan的年基础收入为22万美元，遵照公司薪酬委员会和董事会建立的年度奖励计划，他还可以通过个人表现获得年基础收入30%的奖励。此外，根据就业协议以及加入公司的诱因来看， Henighan获得诱因期权授权，可以够买公司28266股普通股份，按照可改变基础来算，这相当于公司杰出普通股的0.50%。该期权的预购股票价格为4.60美元，是授予日的闭市价格，时间持续三（3）年，股份的三分之一在授予日的第一周年归期权持有人所有；剩余的三分之二股份需要期权持有人在授予日第一周年之后的2年内（期权持有人总共有3年时间）进行8次平等的季度分期付款， Henighan继续在公司任职，每到一次授予时间，他就会得到一部分股份。
Michael P. Henighan has served as our Chief Financial Officer since August 2014. In connection with Mr. Henighan's appointment, we entered into an executive employment agreement with Mr. Henighan, effective August 25, 2014. Under the employment agreement, Mr. Henighan receives an annual base salary of $220,000 per year, and he is eligible to earn an annual performance bonus of up to 30% of his then current base salary in accordance with an annual incentive plan to be established by the Company's compensation committee or the Board. In addition, under the employment agreement and as an inducement to join the Company, Mr. Henighan received an inducement option grant to purchase 28,266 shares of our common stock, which equaled one-half percent (0.50%) of our then outstanding common stock calculated on an as-converted basis. This option has an exercise price of $4.60, which was the closing market price on the grant date, and vests over a period of three (3) years, with one-third of the shares subject to the option vesting on the first anniversary of the grant date, and the remaining two-thirds of the shares subject to the option vesting in eight (8) equal quarterly installments over two years following the one-year anniversary of the grant date (for a three-year vesting period in total), subject to Mr. Henighan's continued employment with the Company through each vesting date.- Michael P. Henighan自2014年8月起担任公司首席财务官。除了 Henighan的此项任命之外，我们还与 Henighan签订了高管就业协议，2014年8月25日正式生效。根据就业协议， Henighan的年基础收入为22万美元，遵照公司薪酬委员会和董事会建立的年度奖励计划，他还可以通过个人表现获得年基础收入30%的奖励。此外，根据就业协议以及加入公司的诱因来看， Henighan获得诱因期权授权，可以够买公司28266股普通股份，按照可改变基础来算，这相当于公司杰出普通股的0.50%。该期权的预购股票价格为4.60美元，是授予日的闭市价格，时间持续三（3）年，股份的三分之一在授予日的第一周年归期权持有人所有；剩余的三分之二股份需要期权持有人在授予日第一周年之后的2年内（期权持有人总共有3年时间）进行8次平等的季度分期付款， Henighan继续在公司任职，每到一次授予时间，他就会得到一部分股份。
- Michael P. Henighan has served as our Chief Financial Officer since August 2014. In connection with Mr. Henighan's appointment, we entered into an executive employment agreement with Mr. Henighan, effective August 25, 2014. Under the employment agreement, Mr. Henighan receives an annual base salary of $220,000 per year, and he is eligible to earn an annual performance bonus of up to 30% of his then current base salary in accordance with an annual incentive plan to be established by the Company's compensation committee or the Board. In addition, under the employment agreement and as an inducement to join the Company, Mr. Henighan received an inducement option grant to purchase 28,266 shares of our common stock, which equaled one-half percent (0.50%) of our then outstanding common stock calculated on an as-converted basis. This option has an exercise price of $4.60, which was the closing market price on the grant date, and vests over a period of three (3) years, with one-third of the shares subject to the option vesting on the first anniversary of the grant date, and the remaining two-thirds of the shares subject to the option vesting in eight (8) equal quarterly installments over two years following the one-year anniversary of the grant date (for a three-year vesting period in total), subject to Mr. Henighan's continued employment with the Company through each vesting date.
- Rolland Carlson
Rolland Carlson，自2015年5月起担任首席执行官、总裁兼董事。他于2006年4月至2014年5月间担任Asuragen, Inc.（分子诊断公司，专注于个性化诊断）的总裁兼董事；2013年1月至2014年5月间担任Asuragen, Inc.的首席执行官，2012年1月至12月间担任首席运营官。在Asuragen, Inc.时，他成立了Mirna Therapeutics（Asuragen的资产剥离公司，开发新型微小核糖核苷酸基础疗法，目前正在进行I期临床试验，用于肝癌和其他癌症）。在加入Asuragen之前， 他在Abbott Laboratories担任了业务开发及许可、全球医疗产品副总裁、the Vysis, Inc.（Abbott的全资子公司）的副总裁和全球总经理等多个高级职位。在他事业早期，他负责业务开发、许可和战略规划，以建立新的制药和诊断平台，用于Abbott的the Ross Division的儿科和女性医疗保健渠道，并且经营着Abbott的全球定制生物制药和特殊仿制药业务。他自2015年4月起担任Pristine, Inc.的董事。他获得了Southern Illinois University - Carbondale的生物学学士学位、运动生理学硕士学位和植物学博士学位。
Rolland Carlson has served as our Chief Executive Officer, President and director since May 2015. Dr. Carlson served as President and Director of Asuragen, Inc., a molecular diagnostic company specializing in personalized diagnostics, from April 2006 to May 2014. Dr. Carlson also served as Chief Executive Officer of Asuragen, Inc. from January 2013 to May 2014 and Chief Operating Officer of Asuragen, Inc. from January 2012 to December 2012. While at Asuragen, Inc., Dr. Carlson founded Mirna Therapeutics, a spin-out of Asuragen, which has developed novel miRNA-based therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to joining Asuragen, Dr. Carlson held several senior positions at Abbott Laboratories, including Vice President, Business Development & Licensing, Global Medical Products and Vice President and Global General Manager of the Vysis, Inc., a wholly-owned subsidiary of Abbott. Earlier in his career, Dr. Carlson was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and women’s health channels of the Ross Division of Abbott, and ran Abbott’s global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson has served on the board of directors of Pristine, Inc. since April 2015. Dr. Carlson received a B.A. in biological sciences, an M.A. in Exercise Physiology and a Ph.D. in Botany from Southern Illinois University - Carbondale.- Rolland Carlson，自2015年5月起担任首席执行官、总裁兼董事。他于2006年4月至2014年5月间担任Asuragen, Inc.（分子诊断公司，专注于个性化诊断）的总裁兼董事；2013年1月至2014年5月间担任Asuragen, Inc.的首席执行官，2012年1月至12月间担任首席运营官。在Asuragen, Inc.时，他成立了Mirna Therapeutics（Asuragen的资产剥离公司，开发新型微小核糖核苷酸基础疗法，目前正在进行I期临床试验，用于肝癌和其他癌症）。在加入Asuragen之前， 他在Abbott Laboratories担任了业务开发及许可、全球医疗产品副总裁、the Vysis, Inc.（Abbott的全资子公司）的副总裁和全球总经理等多个高级职位。在他事业早期，他负责业务开发、许可和战略规划，以建立新的制药和诊断平台，用于Abbott的the Ross Division的儿科和女性医疗保健渠道，并且经营着Abbott的全球定制生物制药和特殊仿制药业务。他自2015年4月起担任Pristine, Inc.的董事。他获得了Southern Illinois University - Carbondale的生物学学士学位、运动生理学硕士学位和植物学博士学位。
- Rolland Carlson has served as our Chief Executive Officer, President and director since May 2015. Dr. Carlson served as President and Director of Asuragen, Inc., a molecular diagnostic company specializing in personalized diagnostics, from April 2006 to May 2014. Dr. Carlson also served as Chief Executive Officer of Asuragen, Inc. from January 2013 to May 2014 and Chief Operating Officer of Asuragen, Inc. from January 2012 to December 2012. While at Asuragen, Inc., Dr. Carlson founded Mirna Therapeutics, a spin-out of Asuragen, which has developed novel miRNA-based therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to joining Asuragen, Dr. Carlson held several senior positions at Abbott Laboratories, including Vice President, Business Development & Licensing, Global Medical Products and Vice President and Global General Manager of the Vysis, Inc., a wholly-owned subsidiary of Abbott. Earlier in his career, Dr. Carlson was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and women’s health channels of the Ross Division of Abbott, and ran Abbott’s global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson has served on the board of directors of Pristine, Inc. since April 2015. Dr. Carlson received a B.A. in biological sciences, an M.A. in Exercise Physiology and a Ph.D. in Botany from Southern Illinois University - Carbondale.